Phillyrin improves myocardial remodeling in salt-sensitive hypertensive mice by reducing endothelin1 signaling

• Published in: Journal of pharmacy and pharmacology Vol. 76; no. 6; p. 672
• Main Authors: Luo, Qingman, Liu, Qiao, Tang, Kecheng, Zhong, Bin, Yang, Shengqian, Li, Xiaohui
• Format: Journal Article
• Language: English
• Published: England 06.06.2024
• Subjects: Animals; Antihypertensive Agents - pharmacology; Blood Pressure - drug effects; Cardiomegaly - drug therapy; Cardiomegaly - metabolism; Cell Line; Desoxycorticosterone Acetate; Disease Models, Animal; Endothelin-1 - metabolism; Fibrosis; Glucosides - pharmacology; Hypertension - drug therapy; Male; Mice; Mice, Inbred C57BL; Myocardium - metabolism; Myocardium - pathology; Signal Transduction - drug effects; Ventricular Remodeling - drug effects; phillyrin; salt-sensitive hypertension; endothelin1; myocardial remodeling
• ISSN: 2042-7158
• DOI: 10.1093/jpp/rgae018

Prolonged exposure to chronic hypertension places the heart under excessive strain, resulting in myocardial remodeling. Phillyrin, derived from the natural plant Forsythia suspensa, has been found to possess cardioprotective properties. The objective of this study is to investigate the role and mechanism of phillyrin in hypertension-induced myocardial remodeling in mice. We constructed a mouse model of salt-sensitive hypertension. The mice were treated with varying doses of phillyrin, and their blood pressure, cardiac function, cardiac hypertrophy, fibrosis, inflammation, and other conditions were assessed. Our research findings demonstrated that phillyrin has the potential to lower blood pressure, enhance cardiac function, and mitigate cardiac hypertrophy, fibrosis, and inflammatory responses in deoxycorticosterone acetate-salt hypertension mice. In hypertensive mice, there was an elevated expression of endothelin1 (ET-1) in heart tissue, which can be reduced by phillyrin. Additionally, phillyrin effectively reduced the hypertrophy of H9c2 cells induced by ET-1 stimulation. Our research highlights the therapeutic capabilities of phillyrin in the treatment of myocardial remodeling through the reduction of ET-1 signaling. These results contribute to the advancement of novel applications for phillyrin and establish a solid conceptual basis for future investigations in this area.